Joseph A. Vetro, Ph.D

Assistant Professor

Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
College of Pharmacy Room 3033
986025 Nebraska Medical Center
Omaha, NE 68198-6025
402-559-9359 (Office)
402-559-1975 (Lab)
402-559-9543 (Fax)
jvetro@unmc.edu

Teaching Activities:

  • Pharmacy Doctorate Students
  • Pharmaceutical Sciences 570: Bioavailability & Bioequivalence, rate processes of drug release, drug absorption, parenterals, biotechnology-derived products, nasal, pulmonary and opthalmic delivery.
  • Pharmaceutical Sciences Graduate Students
  • Quantitative Pharmaceutical Sciences 845: DNA, RNA and proteins
  • Pharm Chem for Drug Delivery 826: Surface modification of micro and nanospheres, synthesis of biodegradable nanogels
  • Innovative Drug Delivery Systems 851: Biological barriers to drug delivery
  • Physical Pharmacy 885: Mass transfer

Research Activities/Interests:

Dr. Vetro's research interests are in developing novel synthetic targeted drug and gene delivery nanocarriers for the anti-angiogenesis treatment of cancer, improving development paradigms for targeted bioimaging and drug delivery nanocarriers and developing subunit vaccines based on the novel adjuvant, EP67.

Please visit the Nanomedicine Group Website for further information.

Recent Publications:

  1. Ambardekar VV, Wakaskar RR, Sharma B, Bowman J, Vayaboury W, Singh RK and Vetro JA (2013). "The efficacy of nuclease-resistant Chol-siRNA in primary breast tumors following complexation with PLL-PEG(5K)."Biomaterials 34(20): 4839-4848.
  2. Ambardekar VV, Han HY, Varney ML, Vinogradov SV, Singh RK and Vetro JA (2011). "The modification of siRNA with 3' cholesterol to increase nuclease protection and suppression of native mRNA by select siRNA polyplexes."Biomaterials 32(5): 1404-1411.
  3. Vetro JA (2006). "Delivery, detection and development in nanomedicine."Nanomedicine 1(4): 487-489.
  4. Batrakova EV, Bronich TK, Vetro JA and Kabanov AV (2006). Polymeric micelles as drug carriers. Nanoparticulates as drug carriers.V. P. Torchilin. London, UK, Imperial College Press: 57-93.
  5. Braun CS, Vetro JA, Tomalia DA, Koe GS, Koe JG and Middaugh CR (2005). "Structure/function relationships of polyamidoamine/DNA dendrimers as gene delivery vehicles."J Pharm Sci 94(2): 423-436.
  6. Vetro JA, Dummitt B, Micka WS and Chang YH (2005). "Evidence of a dominant negative mutant of yeast methionine aminopeptidase type 2 in Saccharomyces cerevisiae."J Cell Biochem 94(4): 656-668.
  7. Vetro JA, Dummitt B and Chang YH (2004). Methionine aminopeptidase: Emerging role in angiogenesis. Aminopeptidases in Biology and Disease.N. M. Hooper and U. Lendeckel. New York, New York, Kluwer: 17-44.
  8. Lobo BA, Vetro JA, Suich DM, Zuckermann RN and Middaugh CR (2003). "Structure/function analysis of peptoid/lipitoid:DNA complexes."J Pharm Sci 92(9): 1905-1918.
  9. Chen S, Vetro JA and Chang YH (2002). "The specificity in vivo of two distinct methionine aminopeptidases in Saccharomyces cerevisiae."Arch Biochem Biophys 398(1): 87-93.
  10. Vetro JA and Chang YH (2002). "Yeast methionine aminopeptidase type 1 is ribosome-associated and requires its N-terminal zinc finger domain for normal function in vivo." J Cell Biochem 85(4): 678-688.

Joseph Vetro, Ph.D.
Dr. Vetro
;